首页> 外文期刊>Oncology reports >Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients
【24h】

Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients

机译:microRNA-26a的下调与转移潜力和骨肉瘤患者预后不良有关

获取原文
获取原文并翻译 | 示例

摘要

Accumulating evidence indicates that microRNAs are involved in multiple processes in cancer development and progression. microRNA-26a (miR-26a) has been identified as a tumor suppressor and its downregulation is associated with poor prognosis in several types of human cancer. However, the specific function of miR-26a in osteosarcoma remains unclear. In the present study, we found that the expression of miR-26a in osteosarcoma tissues and cell lines was much lower than that in the normal controls, respectively. In addition, downregulation of miR-26a more frequently occurred in osteosarcoma specimens with adverse clinical stage and with the presence of distant metastasis. Moreover, multivariate survival analyses demonstrated that loss of miR-26a is an independent prognostic factor for both disease-free and overall survival in osteosarcoma. In addition, restoration of miR-26a expression inhibited the invasion and migration in osteosarcoma cells, and miR-26a directly inhibited enhancer of zeste homolog 2 (EZH2) expression by targeting its 3-UTR. Moreover, EZH2 was upregulated and inversely correlated with miR-26a expression in the osteosarcoma tissues. Thus, for the first time, we provide convincing evidence that downregulation of miR-26a is associated with tumor aggressiveness and tumor metastasis, and miR-26a inhibits cell migration and invasion by targeting the EZH2 gene in osteosarcoma. Thus, miR-26a is an independent prognostic marker for osteosarcoma patients.
机译:越来越多的证据表明,microRNA与癌症的发展和进程有关。 microRNA-26a(miR-26a)被鉴定为肿瘤抑制因子,其下调与几种类型人类癌症的不良预后相关。但是,miR-26a在骨肉瘤中的具体功能仍不清楚。在本研究中,我们发现miR-26a在骨肉瘤组织和细胞系中的表达分别比正常对照组低得多。此外,miR-26a的下调更常发生在临床阶段不良且有远处转移的骨肉瘤标本中。此外,多变量生存分析表明,miR-26a的丢失是骨肉瘤无病生存和总体生存的独立预后因素。此外,miR-26a表达的恢复抑制了骨肉瘤细胞的侵袭和迁移,而miR-26a通过靶向其3-UTR直接抑制zeste同源2(EZH2)表达的增强子。此外,EZH2被上调并且与骨肉瘤组织中的miR-26a表达呈负相关。因此,我们首次提供令人信服的证据,证明miR-26a的下调与肿瘤侵袭性和肿瘤转移有关,而miR-26a通过靶向骨肉瘤中的EZH2基因来抑制细胞迁移和侵袭。因此,miR-26a是骨肉瘤患者的独立预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号